We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Exscientia PLC Sponsored ADR (EXAI) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Exscientia PLC Sponsored ADR (EXAI - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Exscientia PLC Sponsored ADR is a member of our Medical group, which includes 1161 different companies and currently sits at #8 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Exscientia PLC Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for EXAI's full-year earnings has moved 17.1% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, EXAI has gained about 7.1% so far this year. Meanwhile, the Medical sector has returned an average of -7.7% on a year-to-date basis. This shows that Exscientia PLC Sponsored ADR is outperforming its peers so far this year.
Henry Schein (HSIC - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 0.4%.
In Henry Schein's case, the consensus EPS estimate for the current year increased 0.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Exscientia PLC Sponsored ADR belongs to the Medical - Drugs industry, a group that includes 231 individual stocks and currently sits at #153 in the Zacks Industry Rank. Stocks in this group have lost about 11.2% so far this year, so EXAI is performing better this group in terms of year-to-date returns.
In contrast, Henry Schein falls under the Medical - Dental Supplies industry. Currently, this industry has 21 stocks and is ranked #145. Since the beginning of the year, the industry has moved -2.4%.
Investors with an interest in Medical stocks should continue to track Exscientia PLC Sponsored ADR and Henry Schein. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Exscientia PLC Sponsored ADR (EXAI) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Exscientia PLC Sponsored ADR (EXAI - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Exscientia PLC Sponsored ADR is a member of our Medical group, which includes 1161 different companies and currently sits at #8 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Exscientia PLC Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for EXAI's full-year earnings has moved 17.1% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, EXAI has gained about 7.1% so far this year. Meanwhile, the Medical sector has returned an average of -7.7% on a year-to-date basis. This shows that Exscientia PLC Sponsored ADR is outperforming its peers so far this year.
Henry Schein (HSIC - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 0.4%.
In Henry Schein's case, the consensus EPS estimate for the current year increased 0.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Exscientia PLC Sponsored ADR belongs to the Medical - Drugs industry, a group that includes 231 individual stocks and currently sits at #153 in the Zacks Industry Rank. Stocks in this group have lost about 11.2% so far this year, so EXAI is performing better this group in terms of year-to-date returns.
In contrast, Henry Schein falls under the Medical - Dental Supplies industry. Currently, this industry has 21 stocks and is ranked #145. Since the beginning of the year, the industry has moved -2.4%.
Investors with an interest in Medical stocks should continue to track Exscientia PLC Sponsored ADR and Henry Schein. These stocks will be looking to continue their solid performance.